Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

FDA accepts NovaDel's NDA for ZolpiMist oral spray in the treatment of insomnia

Jan. 24, 2008

Johnson & Johnson submits NDA in U.S. for immediate release tapentadol

Jan. 24, 2008

FDA places clinical hold on CytRx's phase IIb clinical trial of arimoclomol for ALS

Jan. 24, 2008

Serenex and CHDI enter agreement to evaluate Hsp90 inhibitors for Huntington's disease

Jan. 23, 2008

StemCells reports death of patient in phase I clinical trial of HuCNS-SC for NCL

Jan. 23, 2008

Novel SMN2 promoter activator by deCODE may be useful in SMA

Jan. 23, 2008

Positive clinical trial results for epilepsy drug rufinamide in mood disorders

Jan. 23, 2008

Novel analgesic agents imparted in recent Vertex and Merck Frosst patents

Jan. 23, 2008

Studies find little benefit of add-on lamotrigine in refractory schizophrenia patients

Jan. 23, 2008

Preclinical characterization of aripiprazole shows uniqueness of D2 partial agonists

Jan. 22, 2008

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...